Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency

Belfield, Kristen; Tichy, Eric M.

doi:10.2146/ajhp160961

Cited by 82 publications

(118 citation statements)

References 52 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…These results are consistent with results from a preliminary study in the country in 2010 [36], and similary to the reports from other studies conducted in other African countries, as Mauritania [37], Uganda [38], Mozambique [39] Senegal [40,41] and Gambia [42]. The high G6PDd prevalence in the African or Afro-descendant population as shown by several studies [39][40][41][42][43] may reflect the population's exposure to malaria endemicity or ethnicity related [8][9][10][11][12][13][14][15][16]. However, our results do not allow drawing any conclusions of this nature since almost all the participants of this study were of Cape Verdean citizenship and no ethnic classification was made.…”

Section: Plos Onesupporting

confidence: 90%

“…The schizontocidal treatment for non-falciparum malaria is done with the AL or Artesunate + Amodiaquine, following the WHO guidelines [7]. Nevertheless, this use of primaquine is carried out regardless the knowledge of the frequency of the Glucose-6-phosphate-dehydrogenase (G6PD) deficiency among the target population, which endangers all the patients harbouring this deficiency with the risk of haemolysis [8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The prevalence of glucose-6-phosphate dehydrogenase deficiency in the Cape Verdean population in the context of malaria elimination

DePina¹,

Pires²,

Andrade³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Cabo Verde aims to eliminate malaria by 2020. In the country, Plasmodium falciparum had been the main parasite responsible for indigenous cases and primaquine is the first line treatment of cases and for radical cure. However, the lack of knowledge of the national prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency may be one of the constraints to the malaria elimination process. Hence, this first study determines the prevalence of G6PD deficiency (G6PDd) in the archipelago. Blood samples were collected from patients who voluntarily agreed to participate in the study, in the health facilities of eight municipalities on four islands, tested with G6PD CareStart ™ deficiency Rapid Diagnosis Test (RDT). All subjects found to be G6PDd by RDT then underwent enzyme quantification by spectrophotometry. Descriptive statistics and inferences were done using SPSS 22.0 software. A total of 5.062 blood samples were collected, in majority from female patients (78.0%) and in Praia (35.6%). The RDT revealed the prevalence of G6PD deficiency in 2.5% (125/5062) of the general population, being higher in males (5.6%) than in females (1,6%). The highest G6PDd prevalence was recorded in São Filipe, Fogo, (5.4%), while in Boavista no case was detected. The G6PDd activity quantification shown a higher number of partially deficient and deficient males (respectively n = 26 and n = 22) compared to females (respectively n = 18 and n = 7), but more normal females (n = 35) than males (n = 11). According to the WHO classification, most of the G6PDd cases belongs to the class V (34.5%), while the Classes II and I were the less represented with respectively 5.8% and zero cases. This study in Cabo Verde determined the G6PDd prevalence in the population, relatively low compared to other

show abstract

Section: Plos Onesupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

The prevalence of glucose-6-phosphate dehydrogenase deficiency in the Cape Verdean population in the context of malaria elimination

DePina¹,

Pires²,

Andrade³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Refractory gout was described in the 2011 ACR recommendations for the diagnosis and management of gout and hyperuricemia, which proposed pegloticase as a potential treatment option [4]. However, because pegloticase is not suitable for patients with G6PD deficiency, and there are about 400 million patients with G6PD deficiency worldwide, the application of pegloticase is limited [10]. Since 2011, refractory gout has not been mentioned in new guidelines or studies.…”

Section: Discussionmentioning

confidence: 99%

Rheumatologists' understanding of Refractory Gout: A questionnaire survey in China

Han

Yin

Cao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Refractory gout is a common problem faced by experienced rheumatologists, relevant research on the difficulties of gout treatment and the understanding of "refractory gout" by rheumatologists is lacking. Methods A total of 910 Chinese rheumatologists attending the annual academic conference on rheumatism completed the electronic questionnaires. The differences in the judgment of refractory gout were analyzed between the senior experience (SE) group and the general experience (GE) group. Results A total of 751 (82.5%) respondents with relevant continuing medical education (CME) were included in our study, including 175 (23.3%) SE rheumatologists and 576 (76.7%) GE rheumatologists. Most of the rheumatologists (715, 95.2%) considered renal function insufficiency as a common complication making gout challenging to treat, while rheumatologists with different experiences had different attitudes towards obesity. For the chronic gouty arthritis patients with one or more tophi, 476 (63.9%) Chinese rheumatologists preferred febuxostat as the first-line treatment option, while 582 (78.3%) chose the maximum daily dose of 80mg for febuxostat, with a higher proportion in SE group than GE group. Meanwhile, the proportion of doctors who chose the dosage of all three uric-lowering drugs consistently with the guidelines was higher in the SE group. Moreover, 123 (70.3%) people in the SE group thought that regardless of the use of drugs for prevention of attack during ULT, the recurrence of symptoms was symptomatic of refractory gout, while fewer in GE group agreed. Similarly, 119 (68.0%) in the SE group thought that failure to achieve the targeted serum uric acid level within 6 months of standardized urate-lowering therapy could be assigned to refractory gout, while fewer in GE group agreed. In terms of personal and social factors, the SE group had a higher percentage of physicians concerned about poor compliance leading to irregular treatment and drug abuse. Conclusions Most of the rheumatologists selected uric-lowering drugs and the maximum dosage of medicines consistently with guidelines. Uncontrolled symptoms, unattainable therapeutic targets, and unimproved lifestyle and compliance of patients are difficulties that Chinese rheumatologists have to face with during gout treatment.

show abstract

“…As there have been a number of case reports showing dapsone to be beneficial [1][2][3], we decided to start her on dapsone therapy. While she did experience improvement in the continuous swelling, she subsequently presented multiple times with recurrent -at times severe -angioedema of the upper lip ( Figure 1c); the latter was successfully managed with high-dose IV corticosteroids and antihistamines.…”

Section: Dear Editorsmentioning

confidence: 99%

Coincidence of cheilitis granulomatosa and chronic spontaneous angioedema: successful treatment with dapsone and omalizumab

Gronostay¹,

Hellmich²,

Rasokat³

et al. 2020

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency

Cited by 82 publications

References 52 publications

The prevalence of glucose-6-phosphate dehydrogenase deficiency in the Cape Verdean population in the context of malaria elimination

The prevalence of glucose-6-phosphate dehydrogenase deficiency in the Cape Verdean population in the context of malaria elimination

Rheumatologists' understanding of Refractory Gout: A questionnaire survey in China

Coincidence of cheilitis granulomatosa and chronic spontaneous angioedema: successful treatment with dapsone and omalizumab

Contact Info

Product

Resources

About